Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Anaplastic Lymphoma Kinase (ALK)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)WithdrawnNCT01500824
What this trial is testing

A Clinical Study Testing The Safety And Efficacy Of Crizotinib In East Asian Patients With Anaplastic Lymphoma Kinase (ALK) Positive Advanced Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
Pfizer
Not applicableUnknownNCT06234579
What this trial is testing

Longitudinal Assessment of Genomic Alterations and Clonal Evolution in ALK-positive NSCLC (Galileo Project)

Who this might be right for
ALK Gene MutationNSCLC Stage IVALK Sensitizing Mutation
Fondazione Policlinico Universitario Agostino Gemelli IRCCS 108
Early research (Phase 1)Study completedNCT02259114
What this trial is testing

A Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003)

Who this might be right for
NUT Midline CarcinomaTriple Negative Breast CancerNon-small Cell Lung Cancer With Rearranged ALK Gene/Fusion Protein or KRAS Mutation+3 more
Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) 47
Testing effectiveness (Phase 2)Study completedNCT03410108
What this trial is testing

Phase 2 Study of Brigatinib in Japanese Participants With Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
ALK-positive Advanced NSCLC
Takeda 104
Large-scale testing (Phase 3)Ended earlyNCT02775006
What this trial is testing

Docetaxel Versus Intercalated Erlotinib-docetaxel in Patients With Relapsed EGFR Wild Type, ALK Negative Non Squamous Cell Carcinoma

Who this might be right for
Carcinoma, Non-small Cell Lung
The Netherlands Cancer Institute 45
Not applicableNo Longer AvailableNCT02784158
What this trial is testing

An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung CancerLung CancerAdvanced Malignancies+1 more
Ariad Pharmaceuticals
Not applicableStudy completedNCT01300429
What this trial is testing

Molecular Determinants of Acquired Clinical Resistance to Crizotinib in Non-small Cell Lung Cancer Harboring a Translocation or Inversion Event Involving the ALK Gene Locus

Who this might be right for
Lung Cancer
Memorial Sloan Kettering Cancer Center 30
Early research (Phase 1)Study completedNCT00585195
What this trial is testing

Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer

Who this might be right for
Non-Small Cell Lung Cancer ALK-positiveNon-Small Cell Lung Cancer c-Met DependentNon-Small Cell Lung Cancer ROS Marker Positive+2 more
Pfizer 596
Testing effectiveness (Phase 2)UnknownNCT04292119
What this trial is testing

Lorlatinib Combinations in Lung Cancer

Who this might be right for
Lung CancerAnaplastic Lymphoma Kinase Gene TranslocationROS1 Rearrangement+4 more
Massachusetts General Hospital 96
Post-approval studies (Phase 4)UnknownNCT03707847
What this trial is testing

Crizotinib Combined With Etoposide Capsule Followed by Auto-HSCT for Relapsed and Refractory ALK+ ALCL

Who this might be right for
ALK-Positive Anaplastic Large Cell Lymphoma
Mingzhi Zhang 20
Not applicableStudy completedNCT02042105
What this trial is testing

A Prospective Epidemiologic Study of ALK-Positive NSCLC in China

Who this might be right for
Non-small-cell Lung Cancer
Guangdong Association of Clinical Trials 3,649
Not applicableUnknownNCT03375437
What this trial is testing

RNASARC - Molecular Screening Program of Soft Tissue Sarcomas With Complex Genomic Profile to Detect NTRK1/2/3, ROS1 or ALK Gene Fusions.

Who this might be right for
Soft Tissue SarcomaAdvanced CancerMetastatic Cancer
Centre Leon Berard 376
Testing effectiveness (Phase 2)Study completedNCT00939770
What this trial is testing

Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma

Who this might be right for
Recurrent Childhood Anaplastic Large Cell LymphomaRecurrent Malignant Solid NeoplasmRecurrent Neuroblastoma+3 more
Children's Oncology Group 122
Early research (Phase 1)Study completedNCT01772797
What this trial is testing

Phase Ib Study of LDK378 and AUY922 in ALK-rearranged Non-small Cell Lung Cancer

Who this might be right for
Anaplastic Lymphoma Kinase (ALK)Non-small Cell Lung Cancer
Novartis Pharmaceuticals 22
Testing effectiveness (Phase 2)Study completedNCT04111705
What this trial is testing

Lorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients With Advanced ALK-positive Non-small Cell Lung Cancer

Who this might be right for
Non Small Cell Lung Cancer Metastatic
Intergroupe Francophone de Cancerologie Thoracique 23
Early research (Phase 1)Ended earlyNCT01121588
What this trial is testing

Studying An Investigational Drug Crizotinib (PF-02341066) In Non Non-Small Cell Lung Cancer Tumors That Are Positive For Anaplastic Lymphoma Kinase (ALK)

Who this might be right for
Neoplasms Malignant
Pfizer 44
Very early researchLooking for participantsNCT06333899
What this trial is testing

Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion

Who this might be right for
High Grade GliomaDiffuse Intrinsic Pontine GliomaAnaplastic Astrocytoma+6 more
Nationwide Children's Hospital 15
Not applicableNot Yet RecruitingNCT07674524
What this trial is testing

Management Strategy of 1L Lorlatinib With Hyperlipidemia in Stage IIIB-IV ALK Positive NSCLC

Who this might be right for
Non-Small Cell Lung Cancer (NSCLC)HyperlipidemiaALK Gene Mutation+1 more
Sun Yat-sen University 160
Testing effectiveness (Phase 2)WithdrawnNCT04260009
What this trial is testing

Pharmacokinetics, Safety, and Efficacy of Brigatinib Monotherapy in Pediatric and Young Adult Participants With ALK+ Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors or Other Solid Tumors

Who this might be right for
Anaplastic Lymphoma Kinase Positive (ALK +) Anaplastic Large Cell LymphomaInflammatory Myofibroblastic TumorsSolid Tumors
Takeda
Early research (Phase 1)Active Not RecruitingNCT03611738
What this trial is testing

Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC

Who this might be right for
Non-small Cell Lung CancerLung CancerNon-small Cell Lung Cancer Metastatic+3 more
H. Lee Moffitt Cancer Center and Research Institute 21
Next Page